{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T01:41:58Z","timestamp":1781228518850,"version":"3.54.1"},"reference-count":24,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013342","name":"NIHR Imperial Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013342","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ijgc.2026.104655","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T18:56:24Z","timestamp":1774464984000},"page":"104655","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparison of efficacy and toxicity of 2 dactinomycin (ACTD) regimens in the second-line treatment of low-risk gestational trophoblastic neoplasia: a retrospective study"],"prefix":"10.1016","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-1680-3118","authenticated-orcid":false,"given":"Leonoor T.A.","family":"Coopmans","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nienke E.","family":"van Trommel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1205-1895","authenticated-orcid":false,"given":"Sara","family":"Balduzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianne","family":"Aguiar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-9894-0662","authenticated-orcid":false,"given":"Firas","family":"Charfare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eshan","family":"Ghorani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reece","family":"Caldwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baljeet","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveed","family":"Sarwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8693-7299","authenticated-orcid":false,"given":"Christianne A.R.","family":"Lok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4078-2599","authenticated-orcid":false,"given":"Michael J.","family":"Seckl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"suppl 1","key":"10.1016\/j.ijgc.2026.104655_bib1","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/ijgo.13877","article-title":"Diagnosis and management of gestational trophoblastic disease: 2021 update","volume":"155","author":"Ngan","year":"2021","journal-title":"Int J Gynaecol Obstet"},{"issue":"6","key":"10.1016\/j.ijgc.2026.104655_bib2","doi-asserted-by":"crossref","first-page":"643.e1","DOI":"10.1016\/j.ajog.2009.03.011","article-title":"Methotrexate for 2000 FIGO low-risk gestational trophoblastic neoplasia patients: efficacy and toxicity","volume":"200","author":"Chalouhi","year":"2009","journal-title":"Am J Obstet Gynecol"},{"issue":"11","key":"10.1016\/j.ijgc.2026.104655_bib3","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1038\/bjc.2012.462","article-title":"Treatment outcomes for 618 women with gestational trophoblastic tumours following a molar pregnancy at the Charing Cross Hospital, 2000\u20132009","volume":"107","author":"Sita-Lumsden","year":"2012","journal-title":"Br J Cancer"},{"issue":"suppl 6","key":"10.1016\/j.ijgc.2026.104655_bib4","doi-asserted-by":"crossref","first-page":"vi39","DOI":"10.1093\/annonc\/mdt345","article-title":"Gestational trophoblastic disease: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"24","author":"Seckl","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijgc.2026.104655_bib5","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2020.02.011","article-title":"Clinical Working Party of the EOTTD. Practical clinical guidelines of the EOTTD for treatment and referral of gestational trophoblastic disease","volume":"130","author":"Lok","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ijgc.2026.104655_bib6","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.bpobgyn.2021.01.006","article-title":"Treatment of low-risk gestational trophoblastic neoplasia","volume":"74","author":"Winter","year":"2021","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"issue":"5","key":"10.1016\/j.ijgc.2026.104655_bib7","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1097\/IGC.0000000000001248","article-title":"Efficacy and safety of second-line 5-day dactinomycin in case of methotrexate failure for gestational trophoblastic neoplasia","volume":"28","author":"Prouvot","year":"2018","journal-title":"Int J Gynecol Cancer"},{"issue":"7","key":"10.1016\/j.ijgc.2026.104655_bib8","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1200\/JCO.2002.07.166","article-title":"Low-risk persistent gestational trophoblastic disease: outcome after initial treatment with low-dose methotrexate and folinic acid from 1992 to 2000","volume":"20","author":"McNeish","year":"2002","journal-title":"J Clin Oncol"},{"issue":"7-8","key":"10.1016\/j.ijgc.2026.104655_bib9","first-page":"279","article-title":"Low-risk gestational trophoblastic neoplasia and methotrexate resistance: predictors of response to treatment with actinomycin D and need for combination chemotherapy","volume":"55","author":"Growdon","year":"2010","journal-title":"J Reprod Med"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104655_bib10","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.ygyno.2016.10.001","article-title":"Risk adapted single-agent dactinomycin or carboplatin for second-line treatment of methotrexate resistant low-risk gestational trophoblastic neoplasia","volume":"143","author":"Winter","year":"2016","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104655_bib11","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.ygyno.2012.03.039","article-title":"Treatment of nonmetastatic and metastatic low-risk gestational trophoblastic neoplasia: factors associated with resistance to single-agent methotrexate chemotherapy","volume":"125","author":"Chapman-Davis","year":"2012","journal-title":"Gynecol Oncol"},{"issue":"6","key":"10.1016\/j.ijgc.2026.104655_bib12","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1002\/cncr.22118","article-title":"Phase II trial of pulse dactinomycin as salvage therapy for failed low-risk gestational trophoblastic neoplasia: a Gynecologic Oncology Group study","volume":"107","author":"Covens","year":"2006","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.ijgc.2026.104655_bib13","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1111\/1471-0528.16198","article-title":"Risk factors for second-line dactinomycin failure after methotrexate treatment for low-risk gestational trophoblastic neoplasia: a retrospective study","volume":"127","author":"Hoeijmakers","year":"2020","journal-title":"BJOG"},{"issue":"7","key":"10.1016\/j.ijgc.2026.104655_bib14","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1200\/JCO.2010.30.4386","article-title":"Phase III trial of weekly methotrexate or pulsed dactinomycin for low-risk gestational trophoblastic neoplasia: a gynecologic oncology group study","volume":"29","author":"Osborne","year":"2011","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104655_bib15","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ijgo.2008.05.013","article-title":"Pulse methotrexate versus pulse actinomycin D in the treatment of low-risk gestational trophoblastic neoplasia","volume":"103","author":"Yarandi","year":"2008","journal-title":"Int J Gynaecol Obstet"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104655_bib16","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1186\/s12885-018-4512-5","article-title":"Pulse actinomycin D as first-line treatment of low-risk post-molar non-choriocarcinoma gestational trophoblastic neoplasia","volume":"18","author":"Li","year":"2018","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104655_bib17","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.ygyno.2004.04.018","article-title":"Single-agent pulse dactinomycin has only modest activity for methotrexate-resistant gestational trophoblastic neoplasia","volume":"94","author":"Chen","year":"2004","journal-title":"Gynecol Oncol"},{"issue":"4","key":"10.1016\/j.ijgc.2026.104655_bib18","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1136\/ijgc-00009577-199607000-00006","article-title":"Decision making for chemotherapy administration in patients with low risk gestational trophoblastic neoplasia","volume":"6","author":"Kohorn","year":"1996","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104655_bib19","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1002\/ijgo.12629","article-title":"Comparison of pulsed actinomycin D and 5-day actinomycin D as first-line chemotherapy for low-risk gestational trophoblastic neoplasia","volume":"143","author":"Mu","year":"2018","journal-title":"Int J Gynaecol Obstet"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104655_bib20","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.ygyno.2020.02.001","article-title":"Effectiveness and toxicity of second-line actinomycin D in patients with methotrexate-resistant postmolar low-risk gestational trophoblastic neoplasia","volume":"157","author":"Maest\u00e1","year":"2020","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104655_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100110","article-title":"Increasing the human chorionic gonadotrophin cut-off to \u22641000 IU\/l for starting actinomycin D in post-molar gestational trophoblastic neoplasia developing resistance to methotrexate spares more women multi-agent chemotherapy","volume":"6","author":"Cort\u00e9s-Charry","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.ijgc.2026.104655_bib22","unstructured":"Protocol development: adverse Events\/CTCAE. C-TEP; Last updated: 19-04-2021. NIH National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) | Protocol Development. (cancer.gov). https:\/\/www.cancer.gov.\/research\/resources\/resource\/210. accessed 01-04-2025"},{"key":"10.1016\/j.ijgc.2026.104655_bib23","unstructured":"Hakkaart-Van Roijen L, Peeters S, Kanters T. Kostenhandleiding voor economische evaluaties in de gezondheidszorg: methodologie en referentieprijzen. Herziene versie 2024. Zorginstituut Nederland. Zorginstituut Nederland. Accessed 31-01-2025. https:\/\/www.zorginstituutnederland.nl\/binaries\/zinl\/documenten\/publicatie\/2024\/01\/16\/richtlijn-voor-het-uitvoeren-van-economische-evaluaties-in-de-gezondheidszorg\/Verdiepingsmodule+Kostenhandleiding+(versie+2024).pdf."},{"issue":"16","key":"10.1016\/j.ijgc.2026.104655_bib24","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1093\/jnci\/djj305","article-title":"Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer","volume":"98","author":"Hassett","year":"2006","journal-title":"J Natl Cancer Inst"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X26001866?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X26001866?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T09:33:37Z","timestamp":1780306417000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X26001866"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S1048891X26001866"],"URL":"https:\/\/doi.org\/10.1016\/j.ijgc.2026.104655","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of efficacy and toxicity of 2 dactinomycin (ACTD) regimens in the second-line treatment of low-risk gestational trophoblastic neoplasia: a retrospective study","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijgc.2026.104655","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Society of Gynaecological Oncology and the International Gynecologic Cancer Society. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104655"}}